
Can Fite Biopharma fell 77.2% from $6.62 to $1.51, behind the S&P 500's +10.2%. Its worst day was Sep 2 (−28.3%), and its low came Nov 13 at $1.42.
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Can Fite Biopharma closed at its highest level of the year, 6.0% above where the year started.
+4.4% · S&P 500 +0.5%
Can Fite Biopharma shares fell 25.0%, while the S&P 500 rose 0.4%.
Story events cover the past 12 months · Times ET
−25.0% · S&P 500 +0.4%
Can Fite Biopharma shares rose 18.3%, while the S&P 500 fell 0.3%.
+18.3% · S&P 500 −0.3%
Can Fite Biopharma shares fell 23.6%, while the S&P 500 fell 0.6%.
−23.6% · S&P 500 −0.6%
EPS of $-5.97 beat the $-10.40 estimate on $405,000.00 revenue (est. $202,000.00).
+1.9% · S&P 500 −1.8%
Can Fite Biopharma shares rose 55.9%, while the S&P 500 fell 0.1%.
+55.9%, the year's best day, on 57M shares, the year's heaviest volume · S&P 500 −0.1%
EPS of $-1.24 beat the $-1.43 estimate on $202,000.00 revenue.
+2.7% · S&P 500 −0.5%
Can Fite Biopharma closed at its lowest level of the year, 78.5% below where the year started.
−4.7% · S&P 500 −0.4%
Where it ended: a close of $1.51 on Nov 18, 2026.
Nothing in the past 12 months.
All CANF dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CANF and SPY from Benzinga historical bars. Not investment advice.